Does lactobacillus vaccine for trichomoniasis, Solco Trichovac, induce antibody reactive with Trichomonas vaginalis?

J. F. Alderete

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Solco Trichovac is a variance of Lactobacillus acidophilus developed for treating trichomoniasis. The efficacy of the vaccine is reportedly due to cross reacting antibody being produced in people immunised with the lactobacillus bacteria. Several techniques, including enzyme linked immunosorbent, indirect immunofluorescence, immunoblot, and radioimmunoprecipitation assays were used to assess the extent of antigenic cross reactivity between Lactobacillus acidophilus and Trichomonas vaginalis. Data show a lack of antigenic relatedness between the Solco Trichovac lactobacilli and several strains of T vaginalis. Furthermore, antiserum to L acidophilus failed to inhibit trichomonad cytadherence or host cell killing, as is suggested by the producers of the Solco Trichovac vaccine.

Original languageEnglish (US)
Pages (from-to)118-123
Number of pages6
JournalGenitourinary Medicine
Volume64
Issue number2
StatePublished - 1988

ASJC Scopus subject areas

  • Dermatology
  • Urology

Fingerprint

Dive into the research topics of 'Does lactobacillus vaccine for trichomoniasis, Solco Trichovac, induce antibody reactive with Trichomonas vaginalis?'. Together they form a unique fingerprint.

Cite this